Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 710

Sort by

Sort Order Select

Journal Articles

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Greta De Jong, Sophie E Levie, Remko Schotte, PhD, Wouter Pos, PhD, Daniel Go, Etsuko Yasuda, Madalina Cercel, Susan E van Hal-van Veen, Esmay Frankin, Anikó Szabó, MD, Julien Villaudy, PhD, Pauline M van Helden, PhD, Hans van Eenennaam, PhD, Hergen Spits, PhD, Anita W Rijneveld, MD PhD, Mette D Hazenberg, MD PhD

Blood (2019) 134 (Supplement_1): 4461.

https://doi.org/10.1182/blood-2019-127894

Published: 2019

Journal Articles

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Zachary Davis, PhD BS, Martin Felices, PhD, Todd R Lenvik, Sujan Badal, Peter Hinderlie, Bruce R. Blazar, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 621.

https://doi.org/10.1182/blood-2019-127261

Published: 2019

Journal Articles

RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade

Simon Heidegger, MD, Alexander Wintges, Florian Stritzke, Katja Steiger, Paul-Albert Koenig, Thomas Engleitner, Julius Clemens Fischer, Vladimir Makarov, Christof Winter, Roland Rad, Marcel R.M. van den Brink, MD PhD, Jürgen Ruland, Florian Bassermann, MD PhD, Timothy Chan, Tobias Haas, MD, Hendrik Poeck, MD

Blood (2019) 134 (Supplement_1): 624.

https://doi.org/10.1182/blood-2019-128724

Published: 2019

Journal Articles

A Unique Crosstalk between Tumor Cells and Hematopoietic Stem Cells Reveals a Myeloid Differentiation Pattern Signature Contributing to Metastasis

Ksenia Magidey, PhD, Ksenya Kveler, PhD, Rachelly Normand, PhD, Tongwu Zhang, PhD, Michael Timaner, PhD, Ziv Raviv, PhD, Brian James, PhD, Roi Gazit, PhD, Ze'ev Ronai, PhD, Shai Shen-Orr, PhD, Yuval Shaked, PhD

Blood (2019) 134 (Supplement_1): 2465.

https://doi.org/10.1182/blood-2019-128126

Published: 2019

Journal Articles

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

Filip Janku, MD PhD, Harsh Patel, BS, Vaijayanthi Kandadai Raghavan, Aaron Goodman, Tamara G. Barnes, Razelle Kurzrock, MD

Blood (2019) 134 (Supplement_1): 2319.

https://doi.org/10.1182/blood-2019-126342

Published: 2019

Journal Articles

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Jason Gotlib, MD MS, Nashat Gabrail, MD, Casey L. O'Connell, MD, Regina Garcia-Delgado, MD, Timothy Sbardellati, Wayne M. Rothbaum, Jesse McGreivy, Claire N Harrison, Professor, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 4168.

https://doi.org/10.1182/blood-2019-123546

Published: 2019

Journal Articles

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, William G Rice, PhD, Stephen B Howell, MD

Blood (2019) 134 (Supplement_1): 5755.

https://doi.org/10.1182/blood-2019-123571

Published: 2019

Journal Articles

Lymphatic Control of the Tumor Immune Microenvironment

Melody A. Swartz, PhD

Blood (2019) 134 (Supplement_1): SCI-46.

https://doi.org/10.1182/blood-2019-123389

Published: 2019

Journal Articles

Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation

Gordon Ruan, MD, Gaurav Goyal, MBBS, Jithma P. Abeykoon, MD, N. Nora Bennani, MD, Karen Rech, MD, Jason Young, MD, Mithun Vinod Shah, MD PhD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 5895.

https://doi.org/10.1182/blood-2019-124891

Published: 2019

Journal Articles

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment

Judith Eckl, PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Petra Prinz-Schulz, PhD, Christiane Fingerhut, Yngvar Floisand, MD PhD, Dag Josefsen, Iris Bigalke, MD, Kai Pinkernell, MDMBA, Gunnar Kvalheim, MD PhD, Dolores Schendel, Prof., Anna Tafuri, MD

Blood (2019) 134 (Supplement_1): 3923.

https://doi.org/10.1182/blood-2019-129749

Published: 2019

Journal Articles

Loss of Asxl1 Cooperates with Oncogenic Nras to Drive CMML Progression

Xiaona You, PhD, Zhi Wen, PhD, Guangyao Kong, Adhithi Rajagopalan, BS, Erik A. Ranheim, MD PhD, Yun Zhou, MS, Mrinal M Patnaik, MDMBBS, Jing Zhang, PhD

Blood (2019) 134 (Supplement_1): 3790.

https://doi.org/10.1182/blood-2019-131347

Published: 2019

Journal Articles

Transcriptome Alterations of Isolated Primary Bone Marrow Endothelial Cells Provide Insigt to MGUS and Multiple Myeloma Pathobiology

Sandro Bräunig, MSc, Dimitra Zacharaki, PhD, Hongzhe Li, PhD, Hooi Ching Lim, PhD, Stefan Lang, PhD, Thoas Fioretos, MD PhD Prof., Stefan Scheding, MD

Blood (2019) 134 (Supplement_1): 4373.

https://doi.org/10.1182/blood-2019-128024

Published: 2019

Journal Articles

Intra-Tumoral CD8+ T-Cells in Follicular Lymphoma Contain Large Clonal Expansions That Are Amenable to Dual-Checkpoint Blockade

Karthik Nath, MBBS, Soi C. Law, Muhammed B. Sabdia, Lilia Merida De Long, Mohamed Shanavas, MD, Joshua W.D. Tobin, MD, Jay Gunawardana, PhD, Frank Vari, PhD, Sarah-Jane Halliday, Annette Hernandez, BS, Donna Cross, Robert J. Bird, FRACP,FRCP,FRCPA,MBBS,MRCP, Colm Keane, MD, Maher K. Gandhi, PhD

Blood (2019) 134 (Supplement_1): 2793.

https://doi.org/10.1182/blood-2019-130050

Published: 2019

Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2927.

https://doi.org/10.1182/blood-2019-132246

Published: 2019

Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2945.

https://doi.org/10.1182/blood-2019-123836

Published: 2019

Journal Articles

Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

Taiga Nishihori, MD, Jonathan L. Kaufman, MD, James E. Hoffman, Kristin Blouch, Sunil Pandit, Emily Butler, Amit Jain, Yuehui Wu, M. Phillip DeYoung, Aisha N. Hasan, Aaron P. Rapoport

Blood (2019) 134 (Supplement_1): 3134.

https://doi.org/10.1182/blood-2019-128059

Published: 2019

Journal Articles

Novel Cellular Immunotherapy Using Allogeneic Vγ9/δ2-T Cells Gene-Modified to Express HTLV-1 P40Tax-Specific TCR for the Treatment of Adult T Cell Leukemia

Hiroshi Fujiwara, MD PhD, Satoshi Okumura, Yoshihiro Miyahara, Linan Wan, Isao Tawara, MD PhD, Tatsuro Jo, MD PhD, Yuetsu Tanaka, PhD, Yoshimasa Tanaka, PhD, Hiroaki Ikeda, Hiroshi Shiku

Blood (2019) 134 (Supplement_1): 3216.

https://doi.org/10.1182/blood-2019-122412

Published: 2019

Journal Articles

Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility

Anna L Brown, PhD, Milena Babic, BMPharBio (Hons), Andreas Schreiber, Jinghua Feng, PhD, Julia Dobbins, BSc (Hons), Peer Arts, PhD, Paul Wang, PhD, Kerry Phillips, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Parvathy Venugopal, PhD MSc, BSc, Susan Branford, PhD FFSc (RCPA), Nicola Poplawski, MD, Christopher N Hahn, PhD, Hamish S Scott, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 3794.

https://doi.org/10.1182/blood-2019-131642

Published: 2019

Journal Articles

Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance

John R Jones, MD, David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, Rachel Sigsworth, Matthew Jenner, MBBS, MRCP, FRCPath, Martin F. Kaiser, Rebecca Mottram, BA, BSc, Mark T Drayson, MB ChB, PhD FRCPath, Gordon Cook, Walter M Gregory, PhD, Roger G. Owen, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Gareth Morgan, MDPhDFRCP

Blood (2019) 134 (Supplement_1): 3132.

https://doi.org/10.1182/blood-2019-127469

Published: 2019

Journal Articles

Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER ® ) Molecules

Sebastian Bunk, PhD, Martin Hofmann, PhD, Felix Unverdorben, PhD, Meike Hutt, PhD, Gabriele Pszolla, PhD, Frank Schwöbel, PhD, Claudia Wagner, PhD, Sara Yousef, PhD, Heiko Schuster, PhD, Sarah Missel, PhD, Oliver Schoor, PhD, Toni Weinschenk, PhD, Harpreet Singh-Jasuja, PhD, Dominik Maurer, PhD, Carsten Reinhardt, MD

Blood (2019) 134 (Supplement_1): 3368.

https://doi.org/10.1182/blood-2019-129958

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade

A Unique Crosstalk between Tumor Cells and Hematopoietic Stem Cells Reveals a Myeloid Differentiation Pattern Signature Contributing to Metastasis

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Lymphatic Control of the Tumor Immune Microenvironment

Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment

Loss of Asxl1 Cooperates with Oncogenic Nras to Drive CMML Progression

Transcriptome Alterations of Isolated Primary Bone Marrow Endothelial Cells Provide Insigt to MGUS and Multiple Myeloma Pathobiology

Intra-Tumoral CD8+ T-Cells in Follicular Lymphoma Contain Large Clonal Expansions That Are Amenable to Dual-Checkpoint Blockade

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

Novel Cellular Immunotherapy Using Allogeneic Vγ9/δ2-T Cells Gene-Modified to Express HTLV-1 P40Tax-Specific TCR for the Treatment of Adult T Cell Leukemia

Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility

Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance

Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER ® ) Molecules

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only